EC approval for Libmeldy
Developed thanks to more than 15 years of research by the San Raffaele Telethon Institute for Gene Therapy in Milan, Libmeldy is the first therapy approved for eligible patients with early-onset MLD
MOREEffective antibodies against SARS-CoV-2
Discovered a group of antibodies associated with reduced mortality in Covid-19 patients
MORE3D models to study Chronic Lymphocytic Leukemia
Researchers seek to understand how cancer cells interact with the microenvironment
MOREHighlights
Scientists discover a new regulator of antiviral and antitumor immunity
Researchers at SR-Tiget identified a novel mechanism responsible for regulating innate...
Muscular Dystrophy: a new possible therapeutic approach
Researchers at San Raffaele succeeded in slowing down skeletal muscle degeneration, in two...
Gene editing: getting closer to clinical application for a rare genetic disease
New study demonstrates that CRIPSR-Cas9 is able to correct the genetic defect underlying...
Research Highlights
Great research leads to great results. Our pioneering science in numbers.
Research integrity
Upholding high standards of quality, trustworthiness and reproducibility
Industry collaborations
Join the excellence. Explore our integrated biomedical innovation pipeline.
Science outreach
Bridging the gap between science and society, for the benefit of both.